Previous 10 | Next 10 |
2023-11-21 15:13:40 ET More on Beam, CRISPR, etc. Intellia: Soon-To-Be Enrollment Completion Brings About Catalysts In 2024 Editas Medicine, Inc. (EDIT) Presents at Stifel 2023 Healthcare Conference (Transcript) Beam Therapeutics: Sale Of Rights To Verve's In Vivo Ca...
2023-11-17 15:41:00 ET Shares of Verve Therapeutics (NASDAQ: VERV) sank as much as 30.7% this week, according to data from S&P Global Market Intelligence . The gene-editing company focused on the cardiovascular market posted updated data on one of its clinical trials with co...
2023-11-16 05:41:00 ET To an outside observer, it might seem like the cards are unfairly stacked against Verve Therapeutics (NASDAQ: VERV) . The clinical-stage biotechnology stock is developing one-and-done therapies that employ a twist on CRISPR-based gene editing. Verve Therap...
2023-11-16 05:20:00 ET Since reporting some early-stage clinical data from one of its gene editing programs on Nov. 12, share prices of Verve Therapeutics (NASDAQ: VERV) are down 42%. But contrary to what you may be assuming based on the drop, no news was reported that regulators we...
2023-11-13 12:36:46 ET Gainers: Tenax Therapeutics ( TENX ) +310% . Tivic Health Systems ( TIVC ) +71% . Montauk Renewables ( MNTK ) +28% . Sohu.com Ltd. ( SOHU ) +24% . INVO Bioscience ( INVO ) +26% . Direct Digital Holdings...
2023-11-13 12:07:23 ET Investors had the weekend to think about the big stock market rally that they've watched over the past couple of weeks, and in general, the mood coming into the new week was still relatively good. Stock indexes generally eased lower, but not by a huge amount, and sent...
2023-11-13 10:00:16 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
2023-11-13 08:22:15 ET Losers: Aclaris Therapeutics ( ACRS ) -85% announces top-line results from 12-Week phase 2b trial of Oral Zunsemetinib . Verve Therapeutics ( VERV ) -38% . Syntec Optics Holdings ( OPTX ) -10% . Motus GI Holdings ( MOTS ...
2023-11-13 06:59:53 ET More on Verve Verve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For Now Cracking The Cholesterol Code: Verve's High-Stakes Bet Verve shares surge to three-month high following Q3 update Verve Therapeutics GAAP EPS o...
LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses Safety Profile Supports Continued Development of VERVE-101 Enrollment Ongoing in the 0.45 mg/kg and 0.6 mg/kg Cohorts with Plans...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...